Promoter holding
64.27%
AB
Alcon Biosciences Private Limited - Due diligence report
A 360° intelligence report on Alcon Biosciences: trust score, financial health, credit view, compliance, directors, growth and distress sign…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Alcon Biosciences — 360° Intelligence Report
Generated from MCA filings & public records82/100
Trust Score
Low Risk
Alcon Biosciences is assessed as Low Risk with a Trust Score of 82/100. Alcon Biosciences is an active private limited indian non-government company incorporated in 1982, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and low financial risk profile.
Report generated on 18 Aug 2026 from the latest processed filings. Alcon Biosciences Private Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
82/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
73/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
80/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
95/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
90/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
80/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
75/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 95/100 Low Risk
- Liabilities ≈ 38% EBITDA - serviceable.
- Moderate gearing (D/E 1.42).
- Profitable - internal accruals available.
- Externally credit-rated (A4).
Charges position: 3 open (24.22 cr) · 4 satisfied (37.16 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Union Bank Of India | 2 | 48.0 cr |
| Others | 2 | 48.0 cr |
| Hdfc Bank Limited | 1 | 48.0 cr |
| Bank Of Baroda | 2 | 48.0 cr |
Compliance Score: 73/100 Moderate
- Company status is Active as per MCA.
- Balance sheet slightly behind (Mar 2024).
- Litigation present in 1 court forum(s).
- Delayed payments to MSME suppliers disclosed (50 disclosure(s)).
- 2 active GST registration(s).
Legal cases on record (1)
05
Director Intelligence
Stability score: 90/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| ADVAIT JAJODIA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VISHAL NARAYANPRASAD JAJODIA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Ashutosh Radheshyam Tripathi | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 3 directors on the board.
- No disqualified or deactivated DINs.
- 3 director exit(s) in the last 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2024)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2025 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
1 allotment(s) · 0 transfer(s)
Promoters hold a minority stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Klous And Kuppler Llc Fz | Subsidiary Company | 74.00% |
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 80 · Distress 75
Growth signals & trust indicators
Steady revenue growth: +2.1x over 4 year(s).
Profit expanded 24% year-on-year.
Net margin improved to 0.86.
EPFO headcount growing - hiring signal.
Operating for 44+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
3 open charge(s) registered - assets are encumbered.
MSME payment delays disclosed - latest outstanding 2.06 cr.
1 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence76/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- 1 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment85/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 3 open charge(s) of 24.22 cr already registered.
- Compliance record supports lending.
Investor view80/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 4 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events30 Sep 2025
Last AGM held
Annual general meeting
01 Sep 2025
Director appointed
Ashutosh Radheshyam Tripathi (Director)
31 Mar 2024
Latest balance sheet
Filed with ROC
07 Nov 2023
Director ceased
RAKESH AYODHYAPRASAD PANDEY
29 Sep 2023
Director ceased
ADVAIT JAJODIA
Director ceased
KALPESH SHARMA
24 Jun 2023
Director appointed
ADVAIT JAJODIA (Director)
30 Aug 2022
Charge created
Hdfc Bank Limited - 2.70 cr
11 Jan 2022
Charge created
Others - 2.41 cr
07 Sep 2018
Charge satisfied
Union Bank Of India
01 Apr 2018
Director ceased
AADYA VISHAL JAJODIA
30 Sep 2016
Director ceased
SWATI VISHAL JAJODIA
08 Apr 2014
Director ceased
SANT KUMAR O KHANDELWAL
05 Mar 2012
Securities allotted
25500.00 Equity Shares - 2.55 cr raised
04 Jan 2011
Charge created
Union Bank Of India - 20.96 cr
10
Key Observations
Auto-generated from the data aboveRevenue grew 61% over the last 4 financial year(s).
Net profit margin moved from 38% to 1.42.
Debt-to-equity stands at 2.1x - manageable leverage.
Net worth is positive.
3 active director(s) / partner(s); board looks stable and experienced.
2 active GST registration(s) indicate ongoing business operations.
Carries an external credit rating of A4 from Crisil.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a minority stake as per the FY 2025 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 1 security allotment(s) - amounts available in the full report.
1 overseas direct investment(s) (ODI) on record - international footprint.
| Company | CIN | Location |
|---|---|---|
| Morya Castor Private Limited | U15549MH2018PTC303970 | Malegaon, Maharashtra, India |
| Apple Formulations Private Limited. | U24121DL2006PTC148648 | Delhi, Delhi, India |
| Imerys Newquest (India) Private Limited | U24297PN2003PTC018363 | Pune City, Maharashtra, India |
| Unicure Remedies | U24230GJ1993PTC019076 | Vadodara, Gujarat, India |
| Leeds Life Sciences Private Limited | U24100DL2007PTC166537 | New Delhi, Delhi, India |
| Ganesh-Group | L24230GJ1995PLC025661 | Anklesvar, Gujarat, India |
| Narendra Polymers Private Limited | U25209DL1980PTC146593 | New Delhi-2, Delhi, India |
| K B Chlorination Private Limited | U24112GJ2009PTC057471 | Vadodara, Gujarat, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Alcon Biosciences before audits and certifications: compliance score 73/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Alcon Biosciences: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 95/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 80/100, margin trends, ownership structure and peer set for Alcon Biosciences - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 82/100, distress signals and MSME payment-delay disclosures - know whether Alcon Biosciences pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Alcon Biosciences - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Alcon Biosciences an active company?
Alcon Biosciences has MCA status “Active” with a compliance score of 73/100 (Moderate).
Is Alcon Biosciences financially healthy?
Alcon Biosciences has a Financial Health Score of 80/100 (Low Risk) based on its filed financial statements.
Should I do business with Alcon Biosciences?
Its overall Trust Score is 82/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Alcon Biosciences?
Promoters hold a minority stake - exact percentages are in the full report. 3 active director(s) are on record.
Does Alcon Biosciences have loans or charges against its assets?
3 open charge(s) are registered against its assets, and 4 earlier charge(s) stand satisfied.
Is Alcon Biosciences up to date with its ROC filings?
Balance sheet slightly behind (Mar 2024). Overall compliance score: 73/100 (Moderate).
Is it risky to lend to Alcon Biosciences?
Its Credit Risk Score is 95/100 (Low Risk). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
